Home / Health / Roche Obesity Drug Aids Diabetes Patients
Roche Obesity Drug Aids Diabetes Patients
22 Sep
Summary
- Roche's experimental drug targets overweight patients with type 2 diabetes.
- The drug demonstrated significant blood sugar reduction in trials.
- Patients lost an average of 15.5% of their body weight during the study.
Swiss drugmaker Roche announced positive outcomes from a mid-stage clinical trial of its experimental obesity drug. The dual-acting medication was administered to overweight or obese patients diagnosed with type 2 diabetes.
Results from the trial indicated that the drug effectively helped participants lower their blood sugar levels. Furthermore, patients experienced significant body weight reduction, with an average loss of 15.5% during the study period.
This advancement places Roche in direct competition with major pharmaceutical companies like AstraZeneca and Amgen. They are all vying for a substantial share of the rapidly expanding and highly profitable obesity drug market, challenging established leaders such as Eli Lilly and Novo Nordisk.
